Mary Jenkins | Senior Manager, IR |
Doug Ingram | President and CEO |
Ian Estepan | EVP and CFO |
Dallan Murray | SVP and Chief Commercial Officer |
Dr. Gilmore O’Neill | EVP, R&D and Chief Medical Officer |
Dr. Louise Rodino-Klapac | EVP and Chief Scientific Officer |
Gena Wang | Barclays |
Tazeen Ahmad | BoA |
Brian Abrahams | RBC Capital Markets |
Alethia Young | Cantor |
Anupam Rama | JP Morgan |
Salveen Richter | Goldman Sachs |
Brian Skorney | Baird |
Gil Blum | Needham & Company |
Ritu Baral | Cowen |
Difei Yang | Mizuho Securities |
John Boyle | William Blair |
Max Skor | Morgan Stanley |
Joseph Schwartz | SVB Leerink |
Ting Liu | UBS |
Yun Zhong | BTIG |
Good afternoon, ladies and gentlemen, and welcome to the Sarepta Therapeutics Second Quarter 2021 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today’s program is being recorded. At this time, I’ll turn the call over to Mary Jenkins, Senior Manager, Investor Relations.